Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice Source: Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018 Year: 2019
Evaluation of CPAP treatment at 3 months as a tool to predict long-term compliance Source: Eur Respir J 2005; 26: Suppl. 49, 724s Year: 2005
Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Evaluation of asthma control and quality of life after 6 months of treatment with FDC Budesonide/Formoterol-BOREAS study. Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019
Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020 Year: 2021
Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Clinically meaningful FEV1 response with reslizumab achieved early and sustained over 52 weeks Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 660s Year: 2006
Clinical outcome in patients treated with omalizumab during pre-approval period in France Source: Eur Respir J 2007; 30: Suppl. 51, 621s Year: 2007
Response to mepolizumab treatment is sustained across 4-weekly dosing periods Source: ERJ Open Res, 6 (3) 00068-2020; 10.1183/23120541.00068-2020 Year: 2020
Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis Source: Eur Respir J 2003; 22: Suppl. 45, 430s Year: 2003
Omalizumab in children with severe asthma (SA): Which parameters improve after a 16 week trial? Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Does omalizumab attenuate blood eosinophilia at 52 weeks; a single centre observation Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Evaluation of quality of life (QOL) in asthma patients during 6 months formoterol therapy Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001
Does daily SMS increase adherence to asthma treatment? A three months follow-up study Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009
Clinical outcome of adult onset asthma in a 15 year follow-up Source: Virtual Congress 2020 – Risk factors for chronic lung diseases Year: 2020
Salmeterol provides sustained health status improvement over 12 months in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002